Meeting of the Chronic Fatigue Syndrome Advisory Committee, 44977-44978 [2015-18444]
Download as PDF
Federal Register / Vol. 80, No. 144 / Tuesday, July 28, 2015 / Notices
V. Attendance and/or Participation at
the Public Meeting
asabaliauskas on DSK5VPTVN1PROD with NOTICES
A. Purpose and Scope of the Meeting
The purpose of this meeting and
public docket is for CDER and CBER to
hear from stakeholders any questions,
concerns, and suggestions regarding the
proposed plans for the scope and
implementation of the quality metrics
reporting program proposed in this
guidance.
B. Questions to Stakeholders
FDA seeks input from stakeholders
and other members of the public on the
following meeting questions:
1. Are there other objective metrics
that FDA should request in advance of
or in lieu of an inspection that FDA
should collect to improve our
understanding of products and
establishments for purposes of more
informed, risk-based inspection
scheduling and identification of
potential product shortages?
2. Are the definitions of the metrics
and associated data requests selected
adequate and clear?
3. Are the metrics requested from
each business segment/type clear and
appropriate?
4. Should the Agency explore
collecting metrics from high-risk
excipient producers, and if so, which
excipients should be considered highrisk and what metrics should apply?
5. Should the Agency explore
collecting metrics from the medical gas
manufacturing industry?
6. Should the Agency add the ‘‘Right
First Time’’ metric (see section I.), and
if so, should the definition be a rework/
reprocessing rate or a measure of lots
manufactured without processing
deviations?
7. What data standards/mechanisms
would be useful to aid reporting and
how should the submissions be
structured?
8. Are there reporting hurdles to
collecting metrics by reporting
establishment/product (segmented by
site) versus by site (segmented by
product), and how can they be
overcome?
9. FDA may consider whether to
require the submission of quality
metrics on a recurring basis. How
frequently should metrics be reported
and/or segmented within the reporting
period (e.g., annually, semiannually, or
quarterly)?
C. Meeting Participation and Request To
Present
The FDA Conference Center at the
White Oak location is a Federal facility
with security procedures and limited
VerDate Sep<11>2014
19:17 Jul 27, 2015
Jkt 235001
seating. Attendance will be free and on
a first-come, first-served basis. If you
wish to attend (either in person or by
Web cast (see Streaming Web Cast of the
Public Meeting)) and/or present at the
meeting, please register for the meeting
and/or make a request for oral
presentations or comments by visiting
https://qualitymetrics-publicmeeting.eventbrite.com on or before
August 7, 2015. The registration request
should contain complete contact
information for each attendee (i.e.,
name, title, affiliation, address, email
address, telephone number, and priority
number(s)). Those without email access
can register by contacting Althea Cuff by
August 7, 2015 (see FOR FURTHER
INFORMATION CONTACT).
FDA will try to accommodate all
persons who wish to make a
presentation. Individuals wishing to
present should identify the number of
the topic, or topics, they wish to address
(see section V.B.). This will help FDA
organize the presentations. FDA will
notify registered presenters of their
scheduled presentation times. The time
allotted for each presentation will
depend on the number of individuals
who wish to speak. Once FDA notifies
registered presenters of their scheduled
times, they are encouraged to submit an
electronic copy of their presentation to
Althea Cuff at Althea.Cuff@fda.hhs.gov
on or before August 7, 2015. If time
permits, individuals or organizations
that did not register in advance may be
granted the opportunity to make a
presentation.
Persons registered to make an oral
presentation are encouraged to arrive at
the meeting room early and check in at
the onsite registration table to confirm
their designated presentation time. An
agenda for the meeting and other
background materials will be made
available 3 days before the meeting at
https://www.fda.gov/Drugs/NewsEvents/
ucm451529.htm. If you need special
accommodations because of a disability,
please contact Althea Cuff (see FOR
FURTHER INFORMATION CONTACT) at least 7
days before the meeting.
Meeting Registration and Request to
Present: The meeting is free and seating
will be on a first-come, first-served
basis. If you wish to attend or make an
oral presentation, see section V.C. for
information on how to register and the
deadline for registration. If you cannot
attend in person, information about how
you can access a live Web cast will be
located at https://www.fda.gov/Drugs/
NewsEvents/ucm451529.htm.
Transcripts: As soon as a transcript is
available, it will be accessible at
https://www.regulations.gov. It may also
be viewed at the Division of Dockets
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
44977
Management (see ADDRESSES). A
transcript will also be available in either
hard copy or on CD–ROM, after
submission of a Freedom of Information
request. Send written requests to the
Division of Freedom of Information
(ELEM–1029), Food and Drug
Administration, 12420 Parklawn Dr.,
Element Bldg., Rockville, MD 20857.
Streaming Web Cast of the Public
Meeting: For those unable to attend in
person, FDA will provide a live Web
cast of the meeting. To join the meeting
via the Web cast, please go to https://
collaboration.fda.gov/qmpm2015/. An
agenda will be posted on the FDA Web
site at https://www.fda.gov/Drugs/News
Events/ucm451529.htm prior to the
meeting.
Docket Comments: Regardless of
attendance at the public meeting,
interested persons may submit either
electronic or written comments
regarding this document to the public
docket (see ADDRESSES) by (see DATES).
Given that time will be limited at the
public meeting, FDA encourages all
interested persons to comment in
writing to ensure that their comments
are considered.
VI. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, https://www.fda.
gov/BiologicsBloodVaccines/Guidance
ComplianceRegulatoryInformation/
default.htm or https://
www.regulations.gov.
Dated: July 23, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–18448 Filed 7–27–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Chronic Fatigue
Syndrome Advisory Committee
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Chronic Fatigue Syndrome Advisory
Committee (CFSAC) will hold a
meeting. The meeting will be open to
the public.
SUMMARY:
E:\FR\FM\28JYN1.SGM
28JYN1
44978
Federal Register / Vol. 80, No. 144 / Tuesday, July 28, 2015 / Notices
The meeting will be held on
Tuesday, August 18, 2015, from 9:00
a.m. until 5:00 p.m., ET and
Wednesday, August 19, 2015, from 9:00
a.m. until 5:00 p.m., ET.
ADDRESSES: Department of Health and
Human Services, Hubert H. Humphrey
Building, 200 Independence Avenue
SW., Room 800, Washington, DC 20201.
For a map and directions to the Hubert
H. Humphrey building, please refer to
https://www.hhs.gov/about/hhh.html.
FOR FURTHER INFORMATION CONTACT: Any
questions about meeting registration or
public comment sign-up should be
directed to CFSACmtg@hhs.gov. Please
direct other inquiries to CFSAC@
hhs.gov.
SUPPLEMENTARY INFORMATION: CFSAC
was established on September 5, 2002 to
advise, consult with, and make
recommendations to the Secretary,
through the Assistant Secretary for
Health, on a broad range of topics
including: (1) The current state of
knowledge and research and the
relevant gaps in knowledge and research
about the epidemiology, etiologies,
biomarkers, and risk factors relating to
myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS), and
identifying potential opportunities in
these areas; (2) impact and implications
of current and proposed diagnosis and
treatment methods for ME/CFS; (3)
development and implementation of
programs to inform the public, health
care professionals, and the biomedical
research communities about ME/CFS
advances; and (4) strategies to improve
the quality of life of ME/CFS patients.
The agenda for this meeting is being
developed and will be posted on the
CFSAC Web site, https://www.hhs.gov/
advcomcfs/ when finalized. The
meeting will be live-video streamed at
https://www.hhs.gov/live and archived
through the CFSAC Web site: https://
www.hhs.gov/advcomcfs/. Listeningonly via telephone will be available on
both days. Call-in information will be
posted on the CFSAC Web site.
Individuals who plan to attend inperson on one or both days will need to
register in advance so that information
can be provided to government security
officials to facilitate entrance to the
building. A registration form should be
downloaded from the CFSAC Web site
(https://www.hhs.gov/advcomcfs/),
completed, and emailed to CFSACmtg@
hhs.gov to facilitate entrance through
building security. Registration will be
open on July 27, 2015. All registration
should be completed by August 13,
2015. Using the same process as above,
members of the media will need to
register at CFSACmtg@hhs.gov. All
asabaliauskas on DSK5VPTVN1PROD with NOTICES
DATES:
VerDate Sep<11>2014
19:17 Jul 27, 2015
Jkt 235001
attendees will be required to show valid
government-issued picture
identification (state or federal) for entry
into the federal building. Attendees will
receive a wrist band that must be worn
the entire time. Security requires all
non-federal employees to be escorted
the entire time they are in the building.
Upon leaving the building for any
reason, persons will be required to
follow the security steps mentioned
above and receive a new wrist band.
Attendance by visitors who are not
U.S. citizens is welcome, but prior
approval is required. A form for nonU.S. citizens can be downloaded from
the CFSAC Web site (https://
www.hhs.gov/advcomcfs/), completed,
and emailed to CFSACmtg@hhs.gov
before August 1, 2015.
Members of the public will have the
opportunity to provide public comment
at the meeting or via telephone.
International calls cannot be
accommodated. Individuals wishing to
provide public comment in-person or
via phone will be required to request
time for public comment by Monday,
August 10, 2015 at the following link:
CFSACmtg@hhs.gov. An email will be
sent by August 13, 2015 to confirm an
individual’s time for public comment.
Each speaker will be limited to three
minutes for public comment. No
exceptions will be made. Priority will be
given to individuals who have not
provided public comment within the
previous year.
You are not required to submit a
written copy of your testimony unless
you wish to have it included in the
public record. Individuals wishing to
submit written comment for the public
record should send an electronic copy
of their written testimony to:
CFSACmtg@hhs.gov by August 13, 2015.
The document for public record must
not exceed 5 single-spaced, typed pages,
using a 12-point typeface; it is preferred
that the document be prepared in the
MS Word format. Please note that PDF
files, hand-written notes, charts, and
photographs will not be posted on the
CFSAC Web site.
Requests to participate in the public
comment and provide written testimony
will not be accepted at CFSAC@hhs.gov.
Please send all questions about public
comment requests or inquiries to
CFSACmtg@hhs.gov.
Only written testimony submitted for
public record and received by August
13, 2015 are part of the official meeting
record; this testimony will be posted to
the CFSAC Web site within 60 days
after the meeting. Materials submitted
should not include sensitive personal
information, such as social security
number, birthdates, driver’s license
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
number, state identification or foreign
country equivalent, passport number,
financial account number, credit or
debit card number. If you wish to
remain anonymous the document must
specify this.
Persons who wish to distribute
printed materials in person (at their own
expense) to CFSAC members during the
meeting should submit one copy for
approval to the Designated Federal
Officer at CFSACmtg@hhs.gov, prior to
August 13, 2015.
Dated: July 17, 2015.
Nancy C. Lee,
Designated Federal Officer, Chronic Fatigue
Syndrome Advisory Committee.
[FR Doc. 2015–18444 Filed 7–27–15; 8:45 am]
BILLING CODE 4150–42–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Public Meeting of the Presidential
Commission for the Study of
Bioethical Issues
Presidential Commission for
the Study of Bioethical Issues, Office of
the Assistant Secretary for Health,
Office of the Secretary, Department of
Health and Human Services.
ACTION: Notice of meeting.
AGENCY:
The Presidential Commission
for the Study of Bioethical Issues (the
Commission) will conduct its twenty
second meeting on September 2, 2015.
At this meeting, the Commission will
continue to discuss the role of
deliberation and deliberative methods to
engage the public and inform
consideration in bioethics, and how to
integrate pubic dialogue into the
bioethics conversation; bioethics
education as a forum for fostering
deliberative skills, and preparing
students to participate in public
dialogue in bioethics; goals and
methods of bioethics education; and
integrating bioethics education across a
range of professional disciplines and
educational levels.
DATES: The meeting will take place on
September 2, 2015, from 9 a.m. to
approximately 5 p.m.
ADDRESSES: Renaissance Washington
Hotel, 999 9th Street NW., Washington,
DC 20001.
FOR FURTHER INFORMATION CONTACT: Lisa
M. Lee, Executive Director, Presidential
Commission for the Study of Bioethical
Issues, 1425 New York Avenue NW.,
Suite C–100, Washington, DC 20005.
Telephone: 202–233–3960. Email:
Lisa.Lee@bioethics.gov. Additional
information may be obtained at
www.bioethics.gov.
SUMMARY:
E:\FR\FM\28JYN1.SGM
28JYN1
Agencies
[Federal Register Volume 80, Number 144 (Tuesday, July 28, 2015)]
[Notices]
[Pages 44977-44978]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18444]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Chronic Fatigue Syndrome Advisory Committee
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will hold a
meeting. The meeting will be open to the public.
[[Page 44978]]
DATES: The meeting will be held on Tuesday, August 18, 2015, from 9:00
a.m. until 5:00 p.m., ET and Wednesday, August 19, 2015, from 9:00 a.m.
until 5:00 p.m., ET.
ADDRESSES: Department of Health and Human Services, Hubert H. Humphrey
Building, 200 Independence Avenue SW., Room 800, Washington, DC 20201.
For a map and directions to the Hubert H. Humphrey building, please
refer to https://www.hhs.gov/about/hhh.html.
FOR FURTHER INFORMATION CONTACT: Any questions about meeting
registration or public comment sign-up should be directed to
CFSACmtg@hhs.gov. Please direct other inquiries to CFSAC@hhs.gov.
SUPPLEMENTARY INFORMATION: CFSAC was established on September 5, 2002
to advise, consult with, and make recommendations to the Secretary,
through the Assistant Secretary for Health, on a broad range of topics
including: (1) The current state of knowledge and research and the
relevant gaps in knowledge and research about the epidemiology,
etiologies, biomarkers, and risk factors relating to myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS), and identifying
potential opportunities in these areas; (2) impact and implications of
current and proposed diagnosis and treatment methods for ME/CFS; (3)
development and implementation of programs to inform the public, health
care professionals, and the biomedical research communities about ME/
CFS advances; and (4) strategies to improve the quality of life of ME/
CFS patients.
The agenda for this meeting is being developed and will be posted
on the CFSAC Web site, https://www.hhs.gov/advcomcfs/ when finalized.
The meeting will be live-video streamed at https://www.hhs.gov/live and
archived through the CFSAC Web site: https://www.hhs.gov/advcomcfs/.
Listening-only via telephone will be available on both days. Call-in
information will be posted on the CFSAC Web site.
Individuals who plan to attend in-person on one or both days will
need to register in advance so that information can be provided to
government security officials to facilitate entrance to the building. A
registration form should be downloaded from the CFSAC Web site (https://www.hhs.gov/advcomcfs/), completed, and emailed to CFSACmtg@hhs.gov to
facilitate entrance through building security. Registration will be
open on July 27, 2015. All registration should be completed by August
13, 2015. Using the same process as above, members of the media will
need to register at CFSACmtg@hhs.gov. All attendees will be required to
show valid government-issued picture identification (state or federal)
for entry into the federal building. Attendees will receive a wrist
band that must be worn the entire time. Security requires all non-
federal employees to be escorted the entire time they are in the
building. Upon leaving the building for any reason, persons will be
required to follow the security steps mentioned above and receive a new
wrist band.
Attendance by visitors who are not U.S. citizens is welcome, but
prior approval is required. A form for non-U.S. citizens can be
downloaded from the CFSAC Web site (https://www.hhs.gov/advcomcfs/),
completed, and emailed to CFSACmtg@hhs.gov before August 1, 2015.
Members of the public will have the opportunity to provide public
comment at the meeting or via telephone. International calls cannot be
accommodated. Individuals wishing to provide public comment in-person
or via phone will be required to request time for public comment by
Monday, August 10, 2015 at the following link: CFSACmtg@hhs.gov. An
email will be sent by August 13, 2015 to confirm an individual's time
for public comment. Each speaker will be limited to three minutes for
public comment. No exceptions will be made. Priority will be given to
individuals who have not provided public comment within the previous
year.
You are not required to submit a written copy of your testimony
unless you wish to have it included in the public record. Individuals
wishing to submit written comment for the public record should send an
electronic copy of their written testimony to: CFSACmtg@hhs.gov by
August 13, 2015. The document for public record must not exceed 5
single-spaced, typed pages, using a 12-point typeface; it is preferred
that the document be prepared in the MS Word format. Please note that
PDF files, hand-written notes, charts, and photographs will not be
posted on the CFSAC Web site.
Requests to participate in the public comment and provide written
testimony will not be accepted at CFSAC@hhs.gov. Please send all
questions about public comment requests or inquiries to
CFSACmtg@hhs.gov.
Only written testimony submitted for public record and received by
August 13, 2015 are part of the official meeting record; this testimony
will be posted to the CFSAC Web site within 60 days after the meeting.
Materials submitted should not include sensitive personal information,
such as social security number, birthdates, driver's license number,
state identification or foreign country equivalent, passport number,
financial account number, credit or debit card number. If you wish to
remain anonymous the document must specify this.
Persons who wish to distribute printed materials in person (at
their own expense) to CFSAC members during the meeting should submit
one copy for approval to the Designated Federal Officer at
CFSACmtg@hhs.gov, prior to August 13, 2015.
Dated: July 17, 2015.
Nancy C. Lee,
Designated Federal Officer, Chronic Fatigue Syndrome Advisory
Committee.
[FR Doc. 2015-18444 Filed 7-27-15; 8:45 am]
BILLING CODE 4150-42-P